Tanya Bell

BioAge Labs, a clinical-stage biopharmaceutical company developing therapies targeting the biology of aging, announced a multi-year collaboration with Novartis worth over $500 million. The partnership aims to identify and validate drug targets for treating diseases related to aging by combining BioAge’s proprietary human longevity datasets with Novartis’ expertise in exercise biology and drug discovery.

Citryll, a biotechnology company focused on developing monoclonal antibody therapies to address immune-mediated inflammatory diseases, has completed an €85 million Series B financing round.

The round was co-led by Johnson & Johnson Innovation – JJDC, Inc., Forbion, and Novartis Venture Fund, with participation from Pureos Bioventures and existing investors including BioGeneration Ventures, Seventure Partners, BOM, Curie Capital, and the company’s founders. The funding will support the clinical development of its lead candidate, CIT-013, and expand its pipeline.

Tasca Therapeutics, a biotechnology company focused on small molecule inhibitors for oncology, has raised $52 million in Series A financing. The round was co-led by Regeneron Ventures and Cure Ventures, with participation from Invus Group. The funds will support the progression of the company’s lead candidate, CP-383, into Phase 1/2 clinical studies and expand its pipeline of drug discovery programs.

AQEMIA, a techbio company teaching atomic scale physics to a generative AI, has announced reaching $100 million in cumulative funding. The milestone coincides with plans for global expansion, starting with a new office in London, UK, set to open in January 2025.

Following the FDA’s October 2024 clearance of Antag Therapeutics’ Investigational New Drug (IND) application for its lead molecule, AT-7687, the Copenhagen-based biopharmaceutical company has announced the successful closing of an €80 million Series A financing round.

Raidium, a french start-up building a radiology-focused artificial intelligence, has raised €16 million in seed funding co-led by Newfund and Kurma Partners, with additional support from investors including the European Innovation Council (EIC). The funding will help develop Raidium’s multimodal foundation model for medical imaging and expand its applications in clinical and research settings.

Stanford-based Jimini Health, a mental health startup founded in 2023, has announced its official launch with $8 million in seed funding from investors, including Zetta Venture Partners, LionBird, PsyMed, and BoxGroup. The company is developing a hybrid therapy model that combines licensed clinicians with AI-supported tools to provide tailored and continuous mental health care.

Novo Holdings has joined a $135 million Series B financing round for Adcendo, a clinical-stage biotechnology company headquartered in Copenhagen, Denmark.

Adcendo is focused on developing first-in-class antibody-drug conjugates (ADCs) to address cancers with high unmet medical needs. ADCs combine targeted antibody delivery with potent drug payloads, offering a precision approach to treating difficult-to-manage cancers while minimizing damage to healthy tissue.

Cradle has secured $73 million in a Series B funding round led by IVP, bringing its total funding to over $100 million. This investment accelerates the adoption of Cradle’s generative AI platform for protein engineering, which is already being deployed in industries such as pharmaceuticals, diagnostics, agriculture, and chemicals.